How to buy Checkmate Pharmaceuticals stock | $16.81

Checkmate Pharmaceuticals, Inc is a biotechnology business based in the US. Checkmate Pharmaceuticals shares (CMPI) are listed on the NASDAQ and all prices are listed in US Dollars. Checkmate Pharmaceuticals employs 21 staff and has a market cap (total outstanding shares value) of USD$405.1 million.

How to buy shares in Checkmate Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Checkmate Pharmaceuticals. Find the stock by name or ticker symbol: CMPI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Checkmate Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$16.81, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Checkmate Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Checkmate Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Checkmate Pharmaceuticals share price

Use our graph to track the performance of CMPI stocks over time.

Checkmate Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-11.

Latest market close	USD$16.81
52-week range	USD$8.92 - USD$19.94
50-day moving average	USD$12.1271
200-day moving average	USD$12.4002
Wall St. target price	USD$25.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Checkmate Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Checkmate Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Checkmate Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Checkmate Pharmaceuticals price performance over time

Historical closes compared with the close of $16.81 from 2020-12-11

1 week (2021-01-07)	10.59%
1 month (2020-12-17)	15.06%
3 months (2020-10-15)	45.16%
6 months (2020-07-13)	N/A

1 year (2020-01-13)	N/A
2 years (2019-01-13)	N/A
3 years (2018-01-13)	N/A
5 years (2016-01-13)	N/A

Checkmate Pharmaceuticals financials

Gross profit TTM	USD$0
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$405.1 million

TTM: trailing 12 months

Shorting Checkmate Pharmaceuticals shares

There are currently 51,918 Checkmate Pharmaceuticals shares held short by investors – that's known as Checkmate Pharmaceuticals's "short interest". This figure is 26% down from 70,160 last month.

There are a few different ways that this level of interest in shorting Checkmate Pharmaceuticals shares can be evaluated.

Checkmate Pharmaceuticals's "short interest ratio" (SIR)

Checkmate Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Checkmate Pharmaceuticals shares currently shorted divided by the average quantity of Checkmate Pharmaceuticals shares traded daily (recently around 12601.45631068). Checkmate Pharmaceuticals's SIR currently stands at 4.12. In other words for every 100,000 Checkmate Pharmaceuticals shares traded daily on the market, roughly 4120 shares are currently held short.

However Checkmate Pharmaceuticals's short interest can also be evaluated against the total number of Checkmate Pharmaceuticals shares, or, against the total number of tradable Checkmate Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Checkmate Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Checkmate Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0039% of the tradable shares (for every 100,000 tradable Checkmate Pharmaceuticals shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Checkmate Pharmaceuticals.

Find out more about how you can short Checkmate Pharmaceuticals stock.

Checkmate Pharmaceuticals share dividends

We're not expecting Checkmate Pharmaceuticals to pay a dividend over the next 12 months.

Checkmate Pharmaceuticals overview

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Checkmate Pharmaceuticals is owned by insiders or institutions?

  Currently 4.422% of Checkmate Pharmaceuticals shares are held by insiders and 86.455% by institutions.

• How many people work for Checkmate Pharmaceuticals?

  Latest data suggests 21 work at Checkmate Pharmaceuticals.

• When does the fiscal year end for Checkmate Pharmaceuticals?

  Checkmate Pharmaceuticals's fiscal year ends in December.

• Where is Checkmate Pharmaceuticals based?

  Checkmate Pharmaceuticals's address is: 245 Main Street, Cambridge, MA, United States, 02142

• What is Checkmate Pharmaceuticals's ISIN number?

  Checkmate Pharmaceuticals's international securities identification number is: US1628181083